BioCentury
ARTICLE | Clinical News

NEJM publishes Phase II renal transplant data for Hansa's IdeS

August 4, 2017 7:50 PM UTC

Combined data from a pair of open-label Phase II trials showed that 24 of 25 highly human leukocyte antigen (HLA)-sensitized patients treated with IdeS from Hansa Medical AB (SSE:HMED) achieved a successful kidney transplantation. Data were published in the New England Journal of Medicine.

The paper combined data from 2 trials conducted in the U.S. and Sweden, respectively, that enrolled HLA-sensitized patients to receive IdeS immediately prior to a kidney transplantation from an HLA-incompatible donor...

BCIQ Company Profiles

Hansa Biopharma AB

BCIQ Target Profiles

Immunoglobulin G (IgG)